Bibliografía
1. Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021;161(4):1118-32. DOI: 10.1053/j.gastro.2021.07.042.
2. Bryant RV, Winer S, Travis SP, et al. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8(12):1582-97. DOI: 10.1016/j.crohns.2014.08.011.
3. Wu KC, Liang J, Qian JM, et al. Chinese consensus on diagnosis and treatment of inflammatory bowel disease. Chinese Journal of Practical Internal Medicine. 2018;38(09):796-813. DOI: 10.19538/j.nk2018090106.
4. Singh S, George J, Boland BS, et al. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018;12(6):635-43. DOI: 10.1093/ecco-jcc/jjy004.
5. Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017;171(7):1678-91 e13. DOI: 10.1016/j.cell.2017.11.009.
6. Andrews JM, Travis SPL, Gibson PR, et al. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Alimentary Pharmacology & Therapeutics. 2009;29(5):459-69. DOI: 10.1111/j.1365-2036.2008.03915.x.
7. Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2012;24(8):958-64. DOI: 10.1097/MEG.0b013e3283545ae3.
8. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007;102(12):2747-53. DOI: 10.1111/j.1572-0241.2007.01511.x.
9. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2-17. DOI: 10.1093/ecco-jcc/jjab178.
10. Crispino P, Pica R, Unim H, et al. Efficacy of mesalazine or beclomethasone dipropionate enema or their combination in patients with distal active ulcerative colitis. Eur Rev Med Pharmacol Sci. 2015;19(15):2830-7.
11. Rubin DT, Cohen RD, Sandborn WJ, et al. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017;11(7):785-91. DOI: 10.1093/ecco-jcc/jjx032.
12. Danese S, Hart A, Dignass A, et al. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX(R) (Cortiment(R)(MMX(R))) for active, mild-to-moderate ulcerative colitis. United European Gastroenterol J. 2019;7(9):1171-82. DOI: 10.1177/2050640619864848.
13. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004;13(8):563-7. DOI: 10.1002/pds.926.
14. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(6):734-41. DOI: 10.1111/j.1365-2036.2008.03782.x.
15. Kiszka-Kanowitz M, Theede K, Thomsen SB, et al. Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial. eClinicalMedicine. 2022;45. DOI: 10.1016/j.eclinm.2022.101332.
16. van Liere E, Bayoumy AB, Mulder CJJ, et al. Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases. Dig Dis Sci. 2022;67(8):4008-19. DOI: 10.1007/s10620-021-07273-y.
17. Singh S, Proudfoot JA, Dulai PS, et al. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018;113(8):1197-205. DOI: 10.1038/s41395-018-0144-2.
18. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400 e3. DOI: 10.1053/j.gastro.2013.10.052.
19. Filippi J, Laharie D, Micherls C, et al. Efficacy of combination therapy for at least 6 months with thiopurines and infliximab in ulcerative colitis patients in clinical remission: a retrospective multicenter experience. J Crohns Colitis. 2015;9(3):252-8. DOI: 10.1093/ecco-jcc/jjv001.
20. Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1289-97. DOI: 10.1111/apt.16050.
21. Hu A, Kotze PG, Burgevin A, et al. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clin Gastroenterol Hepatol. 2021;19(7):1366-76 e2. DOI: 10.1016/j.cgh.2020.07.012.
22. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841-1845. DOI: 10.1056/NEJM199406303302601.
23. Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis. 2013;19(7):1490-8. DOI: 10.1097/MIB.0b013e318281f362.
24. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6(10):1112-6. DOI: 10.1016/j.cgh.2008.04.035.
25. Christensen B, Gibson PR, Micic D, et al. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019;17(3):486-93. DOI: 10.1016/j.cgh.2018.04.060.
26. Ollech JE, Dwadasi S, Rai V, et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020;51(6):637-43. DOI: 10.1111/apt.15616.
27. Buer LCT, Hoivik ML, Warren DJ, et al. Combining Anti-TNF-alpha and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflamm Bowel Dis. 2018;24(5):997-1004. DOI: 10.1093/ibd/izx110.
28. Glassner K, Oglat A, Duran A, et al. The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. J Dig Dis. 2020;21(5):264-71. DOI: 10.1111/1751-2980.12867.
29. Ahmed W, Galati J, Kumar A, et al. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):e361-e79. DOI: 10.1016/j.cgh.2021.03.034.
30. Peyrin-Biroulet L, Demarest S, Nirula A. Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. Autoimmun Rev. 2019;18(2):123-8. DOI: 10.1016/j.autrev.2018.07.014.
31. Chapman TP, Frias Gomes C, Louis E, et al. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(1):73-84. DOI: 10.1111/apt.15771.
32. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63(3):433-41. DOI: 10.1136/gutjnl-2012-304258.
33. Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505. DOI: 10.1136/bmj.j2505.
34. van Schaik T, Maljaars JP, Roopram RK, et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. Inflamm Bowel Dis. 2014;20(12):2292-8. DOI: 10.1097/MIB.0000000000000208.
35. Costantino G, Furfaro F, Belvedere A, et al. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis. 2012;6(5):588-96. DOI: 10.1016/j.crohns.2011.11.007.
36. Privitera G, Pugliese D, Onali S, et al. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev. 2021;20(6):102832. DOI: 10.1016/j.autrev.2021.102832.
37. Privitera G, Onali S, Pugliese D, et al. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. J Crohns Colitis. 2020. DOI: 10.1093/ecco-jcc/jjaa149.
38. Tong JL, Ran ZH. Dual targeted therapy of biologics in inflammatory bowel disease：state-of-the-art. Chin J Inflamm Bowel Dis. 2022;6(2):106-109. DOI: 10.3760/cma.j.cn101480⁃20220318⁃00046